Basis: FMP quote price / unrounded diluted EPS from four consecutive issuer fiscal quarters. Source: stored company filings and market data; unavailable inputs remain N/A.
The P/E ratio is N/A as of 2026-10-06T21:02:14.254Z.
Calculation as of: 2026-10-06T21:02:14.254Z.
Quote observation: 2026-10-06T20:00:01.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 49c5230cca2432c6fd0637270100fe2f3d02ebc9238e4fdbb1f4ddcca099658b
PE RATIO
N/A
Market Cap
$2.38M
PE Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
| NAME | MARKET CAP | PE RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| iSpecimen Inc. (ISPC) | $2.69M | N/A | N/A | N/A | N/A |
| Universe Pharmaceuticals Inc. (UPC)vs › | $2.66M | N/A | N/A | N/A | N/A |
| Nuwellis, Inc. (NUWE)vs › | $2.56M | N/A | 0.58 | 0.58 | 0.58 |
| bioAffinity Technologies, Inc. (BIAF)vs › | $2.54M | N/A | N/A | N/A | N/A |
| IceCure Medical Ltd (ICCM)vs › | $2.86M | N/A | N/A | N/A | N/A |
| Revelation Biosciences, Inc. (REVB)vs › | $2.94M | N/A | 0.90 | 0.90 | 0.90 |
| Jaguar Health, Inc. (JAGX)vs › | $2.44M | N/A | N/A | N/A | N/A |
| Moleculin Biotech, Inc. (MBRX)vs › | $2.38M | N/A | N/A | N/A | N/A |
| Shuttle Pharmaceuticals Holdings, Inc. (SHPH)vs › | $2.38M | N/A | N/A | N/A | N/A |
| Onconetix, Inc. (ONCO)vs › | $2.37M | N/A | N/A | N/A | N/A |
Trailing P/E
N/A
Forward P/E
N/A
PE Ratio = Share Price / Diluted EPS (TTM)
The price-to-earnings ratio measures how much investors pay for each dollar of trailing earnings. A lower PE can indicate a cheaper valuation; a higher PE implies higher growth expectations.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
